ERK1/2 antibody (N-Term)
Quick Overview for ERK1/2 antibody (N-Term) (ABIN3031825)
Target
See all ERK1/2 (MAPK1/3) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- N-Term
-
Purification
- Antigen affinity
-
Immunogen
- An amino acid sequence from the N-terminus of human MAPK1/3 (ARVADPDHDHTGFL) was used as the immunogen for this MAPK1/3 antibody (100% homologous in human, mouse and rat).
-
Isotype
- IgG
-
-
-
-
Application Notes
- The stated application concentrations are suggested starting amounts. Titration of the MAPK1/3 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 0.5-1 μg/mL,IHC (Paraffin): 0.5-1 μg/mL
-
Restrictions
- For Research Use only
-
-
-
Buffer
- 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water
-
Storage
- -20 °C
-
Storage Comment
- After reconstitution, the MAPK1/3 antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.
-
-
- ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
-
Alternative Name
- MAPK1/3
-
Background
- MAPK1(ERK2) shares high homology with MAPK3(ERK1). MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Mitogen-activated protein(MAP) kinases [also known as Erks] have been established to function as important mediators of signal transduction by growth factor receptors. ERK1/ERK2-dependent activation of endogenous ribosomal transcription, while inactivation of ERK1/ERK2 causes an equally immediate reversion to the basal transcription level. ERK1/ERK2 was found to phosphorylate the architectural transcription factor UBF at amino acids 117 and 201 within HMG boxes 1 and 2, preventing their interaction with DNA. Mutation of these sites inhibited transcription activation and abrogated the transcriptional response to ERK1/ERK2.
-
UniProt
- P28482
Target
-